A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

Not Applicable

Completed

• Conditions: Herpes Simplex; HIV Infections

• Registration Number: NCT00002084
• Lead Sponsor: Glaxo Wellcome

Brief Summary

To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.

Detailed Description

Not available

Study Timeline

• Status Verified: 1996-04
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (46)

Univ of South Alabama; 🇺🇸 Mobile, Alabama, United States

Univ of Arizona / Health Science Ctr; 🇺🇸 Tucson, Arizona, United States

Combat Group; 🇺🇸 Los Angeles, California, United States

Los Angeles County - USC Med Ctr; 🇺🇸 Los Angeles, California, United States

Infectious Disease Med Group / Adult Immunology Clinic; 🇺🇸 Oakland, California, United States

UCI Med Ctr; 🇺🇸 Orange, California, United States

UCSD Med Ctr; 🇺🇸 San Diego, California, United States

San Diego Naval Hosp; 🇺🇸 San Diego, California, United States

ViRx Inc; 🇺🇸 San Francisco, California, United States

UCSF - San Francisco Gen Hosp; 🇺🇸 San Francisco, California, United States

Scroll for more (36 remaining)